COVID-19, Myocarditis and Pericarditis
Circulation Research · 12.05.2023 · 132 (10) · 1302-1319
DOI: 10.1161/circresaha.123.321878 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Circulation Research, erschienen am 12.05.2023. Verfasst von DeLisa Fairweather und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine (D.F., D.J.B., D.N.D., L.T.C.), Mayo Clinic, Jacksonville, FL. Hauptthemen laut MEDLINE: COVID-19, COVID-19 Vaccines, Myocarditis, Pericarditis. Die Arbeit wurde bisher 174-mal zitiert (Crossref) und nennt 198 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, NIAID NIH HHS, NHLBI NIH HHS.
Abstract (Originalsprache)
Viral infections are a leading cause of myocarditis and pericarditis worldwide, conditions that frequently coexist. Myocarditis and pericarditis were some of the early comorbidities associated with SARS-CoV-2 infection and COVID-19. Many epidemiologic studies have been conducted since that time concluding that SARS-CoV-2 increased the incidence of myocarditis/pericarditis at least 15× over pre-COVID levels although the condition remains rare. The incidence of myocarditis pre-COVID was reported at 1 to 10 cases/100 000 individuals and with COVID ranging from 150 to 4000 cases/100 000 individuals. Before COVID-19, some vaccines were reported to cause myocarditis and pericarditis in rare cases, but the use of novel mRNA platforms led to a higher number of reported cases than with previous platforms providing new insight into potential pathogenic mechanisms. The incidence of COVID-19 vaccine-associated myocarditis/pericarditis covers a large range depending on the vaccine platform, age, and sex examined. Importantly, the findings highlight that myocarditis occurs predominantly in male patients aged 12 to 40 years regardless of whether the cause was due to a virus-like SARS-CoV-2 or associated with a vaccine—a demographic that has been reported before COVID-19. This review discusses findings from COVID-19 and COVID-19 vaccine-associated myocarditis and pericarditis considering the known symptoms, diagnosis, management, treatment, and pathogenesis of disease that has been gleaned from clinical research and animal models. Sex differences in the immune response to COVID-19 are discussed, and theories for how mRNA vaccines could lead to myocarditis/pericarditis are proposed. Additionally, gaps in our understanding that need further research are raised.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine (D.F., D.J.B., D.N.D., L.T.C.), Mayo Clinic, Jacksonville, FL.
- Department of Environmental Health Sciences and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (D.F.,).
- Center for Clinical and Translational Science, Mayo Clinic, Rochester, MN (D.F., D.J.B., D.N.D.).
- Mayo Clinic Graduate School of Biomedical Sciences (D.J.B., D.N.D.), Mayo Clinic, Jacksonville, FL.
- Deutsches Herzzentrum der Charité, Berlin, Germany (N.M., B.H.).
ORCID-Profile: DeLisa Fairweather, Bettina Heidecker, Leslie T Cooper
Förderung
- NCATS NIH HHS
- NIAID NIH HHS
- NHLBI NIH HHS
Zitieren
APA
Fairweather, D., Beetler, D. J., Di Florio, D. N., Musigk, N., Heidecker, B., & Cooper, L. T. (2023). COVID-19, Myocarditis and Pericarditis. Circulation Research, 132(10), 1302-1319. https://doi.org/10.1161/circresaha.123.321878
Vancouver
Fairweather D, Beetler DJ, Di Florio DN, Musigk N, Heidecker B, Cooper LT. COVID-19, Myocarditis and Pericarditis. Circulation Research. 2023;132(10):1302-1319. doi:10.1161/circresaha.123.321878
BibTeX
@article{Fairweather2023,
author = {Fairweather, DeLisa and Beetler, Danielle J and Di Florio, Damian N and Musigk, Nicolas and Heidecker, Bettina and Cooper, Leslie T},
title = {COVID-19, Myocarditis and Pericarditis},
journal = {Circulation Research},
year = {2023},
volume = {132},
number = {10},
pages = {1302--1319},
doi = {10.1161/circresaha.123.321878}
}
EUVIMED